14 studies on ARA-290 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently tracks 427 published third-party lab tests of ARA-290 across 226 identified manufacturers. Among reports with a positive numeric purity result, the average is 98.84%. Within this published corpus, 8 positive purity results were below 90%, and 8 reports showed measured quantity more than 10% below the label claim. These are batch-level observations, not guarantees of product identity, safety, or vendor quality.
As of 2026-09-03, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 10 mg | $10.50 | $10.50–$10.50 | $1.05 | 1 source · 1 offer |
| 16 mg | $14.00 | $14.00–$14.00 | $0.88 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. The refresh date is the catalog build date; individual source observation dates are not available in this snapshot. View full price methodology →
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
Within that total, 102 batches have unresolved manufacturer identity. They remain in corpus-level lab evidence and are excluded from named-manufacturer rankings.
Eligible vendors have at least 2 deduplicated tests and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and test count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes tested batches, not every product or shipment, and is not an endorsement.
| Rank | Manufacturer | Tests | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 16 | 99.09% | 0 of 15 (0.0%) 0 0% / not detected · 0 wrong compound · 1 unclassified | Reveal with Pro → | |
| #2 | 10 | 98.09% | 0 of 10 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #3 | 5 | 99.79% | 0 of 5 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Manufacturer identities are included with Pro. Batch counts and lab measurements remain visible.
Recent certificates: #100134 (99.87%) · #100895 (99.39%) · #101047 (99.63%) · #101142 (99.07%) · #101200 (99.81%) · #99690 (99.31%)
This comprehensive review consolidates critical knowledge on tissue-protective cytokines, particularly EPO, making it a valuable resource for researchers and clinicians. The detailed experimental protocols included in…
This research highlights the critical role of early monocyte modulation in influencing the trajectory of Alzheimer's disease (AD) pathology. The findings suggest that ARA 290 could represent a novel therapeutic strate…
This study provides compelling evidence that pHBSP can effectively reverse key pathological features of preeclampsia, particularly endothelial dysfunction and hypertension, in an animal model. The ability of pHBSP to …
This study's findings are significant because 99mTc-DOTA-ARA-290 offers a potentially superior method for non-invasive detection of cardiac ischemia, which could lead to earlier diagnosis and intervention. The high sp…
This research provides compelling evidence for ARA290's potential as a powerful cytoprotective agent, specifically in safeguarding healthy cells from the severe genotoxicity and oxidative stress induced by doxorubicin…
This study provides compelling mechanistic evidence that ARA290 can effectively protect against cisplatin-induced nephrotoxicity by simultaneously suppressing apoptosis and inflammation. The ability of ARA290 to targe…
This research introduces a potentially groundbreaking therapeutic strategy for combating age-related cardiovascular diseases. By utilizing a small erythropoietin-derived non-hematopoietic peptide, the study successful…
This research highlights ARA290 as a promising neuroprotective agent that directly safeguards brain tissue from the devastating effects of ischemic stroke. By targeting the β-common receptor, ARA290 offers a novel mec…
This research highlights a critical, selective impact of immunometabolic dysregulation on executive cognitive function, a domain essential for planning, problem-solving, and decision-making. The findings suggest that …
The exploration of ARA 290, a non-hematopoietic erythropoietin analogue, holds significant promise as it targets a novel mechanism for glucose regulation, potentially offering a new therapeutic avenue beyond existing …
If the study's hypothesis of a positive shift in emotional processing was confirmed, it would represent a significant step forward in neuroscience and psychopharmacology. This could establish ARA290 as a promising can…
Free, no account — handy when you're working with ARA-290.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$12 monthly or $33 lifetime
Create free account